论文部分内容阅读
目的从经济学角度分析4种抗菌药物下呼吸道感染治疗方案,为安全、合理、经济用药提供依据。方法将375例下呼吸道感染患者随机分为阿奇霉素组(A组);左氧氟沙星组(B组);头抱曲松组(C组),头孢哌酮钠舒巴坦钠组(D组)。对4种方案进行成本-效果分析。结果 A、B、C、D组成本分别为90.30元、421.40元、129.50元、406.00元。有效率分别为:89.47%、92.47%、90.43%、93.55%。成本-效果比分别为1.01、4.56、1.43、4.34。结论从药物经济学角度分析阿奇霉素治疗下呼吸到感染较好。
Objective To analyze the treatment regimens of four kinds of lower respiratory tract infections of antibacterials from the perspective of economics and provide the basis for safe, reasonable and economical medication. Methods 375 patients with lower respiratory tract infection were randomly divided into azithromycin group (A group), levofloxacin group (B group), ceibakusone group (C group) and cefoperazone sodium and sulbactam sodium group (D group). Cost-effectiveness analysis of 4 options. Results A, B, C, D group costs were 90.30 yuan, 421.40 yuan, 129.50 yuan, 406.00 yuan. Effective rates were: 89.47%, 92.47%, 90.43%, 93.55%. The cost-effectiveness ratio was 1.01, 4.56, 1.43, 4.34 respectively. Conclusion From the perspective of pharmacoeconomics analysis of azithromycin treatment of respiratory tract infection is better.